VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
31/12/2024
Total Debt19.315.019.219.2
Net Debt8.5-15.55.75.7
Total Debt/Equity0.080.050.060.06
Net Debt/Equity0.04-0.060.020.02
Total Debt/EBITDA0.240.160.220.22
Net Debt/EBITDA0.11-0.160.070.05
Interest Coverage (EBIT/Interest)38.0224.2724.7924.79
Total Debt/Total Capital %7.635.055.665.66
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.